This database contains 125 studies, archived under the term: "Alzheimer"
Click here to filter this large number of results.
One-year repeated cycles of cognitive training (CT) for Alzheimer’s disease
Bergamaschi, Susanna,
Arcara, Giorgio,
Calza, Attilio,
Villani, Daniele,
Orgeta, Vasiliki,
Mondini, Sara
Background: Recent research suggests that a combination of both pharmacological and psychosocial treatments targeting cognitive functions improves cognition in patients with Alzheimer’s disease (AD). The present study evaluated the effectiveness of a 1-year cognitive training (CT) by comparing the cognitive performance of 16 patients with AD treated with CT and cholinesterase inhibitors (ChEIs) (experimental group) […]
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
Beauchet, Olivier,
Launay, Cyrille P.,
Allali, Gazan,
Watfa, Gilles,
Gallouj, Karim,
Herrmann, François R.,
Annweiler, Cedric
Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
Herrschaft, Horst,
Nacu, Anatol,
Likhachev, Sergey,
Sholomov, Ilya,
Hoerr, Robert,
Schlaefke, Sandra
A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease
Cummings, Jeffrey,
Froelich, Lutz,
Black, Sandra E.,
Bakchine, Serge,
Bellelli, Giuseppe,
Molinuevo, José L.,
Kressig, Reto W.,
Downs, Pamela,
Caputo, Angelika,
Strohmaier, Christine
Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.; Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial
Fox, Chris,
Crugel, Monica,
Maidment, Ian,
Auestad, Bjorn Henrik,
Coulton, Simon,
Treloar, Adrian,
Ballard, Clive,
Boustani, Malaz,
Katona, Cornelius,
Livingston, Gill
Background: Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary […]
Acupressure in insomnia and other sleep disorders in elderly institutionalized patients suffering from Alzheimer’s disease
Simoncini, M.,
Gatti, A.,
Quirico, P. E.,
Balla, S.,
Capellero, B.,
Obialero, R.,
D'Agostino, S.,
Sandri, N.,
Pernigotti, L. M.
BACKGROUND: Sleep disorders are very common in elderly institutionalized people with dementia and acupressure recently has been associated with conventional medicine in their treatment. AIMS: Exploring the effectiveness of acupressure for the treatment of insomnia and other sleep disturbances and we want to show that the acupressure treatment is feasible also in elderly resident patients. […]
The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design
Andersen, Fred,
Viitanen, Matti,
Halvorsen, Dag S.,
Straume, Bjørn,
Wilsgaard, Tom,
Engstad, Torgeir A.
Background: Progressive neurodegeneration in Alzheimer’s disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed to study the effect of stimulation therapy and the additional effect of donepezil […]